NO20004222D0 - HLA-linked pre-eclampsia and abortion susceptibility gene - Google Patents

HLA-linked pre-eclampsia and abortion susceptibility gene

Info

Publication number
NO20004222D0
NO20004222D0 NO20004222A NO20004222A NO20004222D0 NO 20004222 D0 NO20004222 D0 NO 20004222D0 NO 20004222 A NO20004222 A NO 20004222A NO 20004222 A NO20004222 A NO 20004222A NO 20004222 D0 NO20004222 D0 NO 20004222D0
Authority
NO
Norway
Prior art keywords
eclampsia
abortion
hla
susceptibility gene
linked pre
Prior art date
Application number
NO20004222A
Other languages
Norwegian (no)
Other versions
NO20004222L (en
Inventor
Margaret O'brien
John Bermingham
Kathleen A Quane
David M Jenkins
Tommie V Mccarthy
Original Assignee
Nat Univ Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland filed Critical Nat Univ Ireland
Publication of NO20004222D0 publication Critical patent/NO20004222D0/en
Publication of NO20004222L publication Critical patent/NO20004222L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
NO20004222A 1998-02-25 2000-08-23 HLA-linked pre-eclampsia and abortion susceptibility gene NO20004222L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE980134 1998-02-25
IE980668 1998-08-12
PCT/IE1999/000012 WO1999043851A1 (en) 1998-02-25 1999-02-25 Hla linked pre-eclampsia and miscarriage susceptibility gene

Publications (2)

Publication Number Publication Date
NO20004222D0 true NO20004222D0 (en) 2000-08-23
NO20004222L NO20004222L (en) 2000-10-24

Family

ID=26320158

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004222A NO20004222L (en) 1998-02-25 2000-08-23 HLA-linked pre-eclampsia and abortion susceptibility gene

Country Status (6)

Country Link
EP (1) EP1056886A1 (en)
JP (1) JP2003517267A (en)
AU (2) AU2636399A (en)
CA (1) CA2321223A1 (en)
NO (1) NO20004222L (en)
WO (1) WO1999043851A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
EP1224465B1 (en) 1999-09-27 2005-12-21 Clifford L. Librach Detection of hla-g
DE19952509A1 (en) * 1999-11-03 2001-05-31 Grosse Wilde Hans Polyclonal antiserum against human leucocyte antigen-G, useful for predicting success of in vitro fertilization and for prognosis of melanoma
FR2810047B1 (en) * 2000-06-13 2004-04-02 Commissariat Energie Atomique NEW ISOFORM OF HLA-G AND ITS APPLICATIONS
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US20050287556A1 (en) * 2004-05-06 2005-12-29 Carole Ober Use of HLA-G genotyping in immune-mediated conditions
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
EP1859051A4 (en) * 2005-03-18 2009-08-05 Univ Hong Kong Chinese Markers for prenatal diagnosis and monitoring
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2007087539A2 (en) * 2006-01-24 2007-08-02 The University Of Chicago Snp binding site for micrornas in hla-g
AU2007264371A1 (en) * 2006-06-30 2008-01-03 Clifford L. Librach Method of detecting preeclampsia
EP1944611A1 (en) * 2007-01-11 2008-07-16 Université de la Méditerranée Biomarker for the medicine and the biology of the reproduction
WO2008148161A1 (en) * 2007-06-07 2008-12-11 Simons Haplomics Limited In situ methods for gene mapping and haplotyping
GB0804662D0 (en) * 2008-03-13 2008-04-16 Guy S & St Thomas S Nhs Founda Drug response marker
CN110187119B (en) * 2008-10-31 2022-07-29 耶鲁大学 Methods and compositions for the detection and treatment of preeclampsia
FR2953023B1 (en) * 2009-11-23 2011-12-09 Commissariat Energie Atomique USE OF AN ISOFORM OF HLA-G AS A MARKER OF OSTEOGENESIS
US10131947B2 (en) * 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
EP3648110A1 (en) * 2018-11-02 2020-05-06 Immune Compass Ltd. System for screening for a disorder linked to the immune system
JP2022538494A (en) * 2019-07-05 2022-09-02 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング HLA-H in medicine and diagnostics
EP4048816A1 (en) * 2019-10-25 2022-08-31 Intellexon GmbH Hla class i molecules in in vitro fertilization and further medical implications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (en) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcripts of the HLA-G class I MHC gene and their applications.
WO1995031472A1 (en) * 1994-05-18 1995-11-23 Board Of Regents, The University Of Texas System Chimeric mhc class i antigens for inducing allograft tolerance
CA2213620A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g

Also Published As

Publication number Publication date
WO1999043851A1 (en) 1999-09-02
AU2003231618A1 (en) 2003-09-11
EP1056886A1 (en) 2000-12-06
CA2321223A1 (en) 1999-09-02
NO20004222L (en) 2000-10-24
JP2003517267A (en) 2003-05-27
AU2636399A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
NO20004222D0 (en) HLA-linked pre-eclampsia and abortion susceptibility gene
DE69842016D1 (en) MICROSTRUCTURE LEADER ANTENNA AND GROUP ANTENNA
GB9720148D0 (en) Gene silencing materials and methods
DE69840172D1 (en) RNA EXPORTELEMENT
NO994009D0 (en) Gene sequencer and methods
DE69828963D1 (en) WIRSTOFFABGE AND GENTHERAPY SYSTEM
DE69836432D1 (en) BILDCODER AND DECODER
DE59505847D1 (en) PSEUDOCERAMIDE
DE69806864T2 (en) Antistatic tire
AP2001002189A0 (en) Genes and proteins and their uses
DE69942195D1 (en) Process system and procedure
DE69811548D1 (en) Antistatic tire
DE69842206D1 (en) ECHOUNTERDRUCKS AND ECHOUNTERPRESSION PROCESSES
DK0967286T3 (en) Leucinaminopeptodase gene
EP1122798A4 (en) Photointerrupter and case thereof
DE69926005D1 (en) CARBAMATE AND CARBAZATE KETOLIDANTIBIOTICS
EP1142999A4 (en) Novel protein and dna thereof
HUP0104954A3 (en) Prv-1 gene and the use thereof
FI972010A0 (en) Arrangements and arrangements
EP1111047A4 (en) Novel protein and dna thereof
KR970056581U (en) Buffer Steik Eisen
DE59812220D1 (en) HOLDING AND WEARBAND
EP1122312A4 (en) Novel protein war-1 and gene thereof
GB9818235D0 (en) Gene and use thereof
SE9801035D0 (en) New DNA sequences and proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application